Home β€Ί Stock analysis β€Ί EOCN

Galmed Pharmaceuticals (EOCN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

EOCN slides 6.6% to $2.85, a 52-week low. Closed at $2.85, -6.55% vs the prior close of $3.05. Day range $2.33–$3.09, opened at $2.91.

Last close$2.85-6.55%
Day range2.33–3.09
Open2.91
Volume10.97K
52-week range2.33–12.32
Avg volume (20d)7.38K

EOCN daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” EOCN slides 6.6% to $2.85, a 52-week low
Oct 15, 2026 β€” EOCN rises 1.3% to $3.05
Oct 14, 2026 β€” EOCN slides 4.9% to $3.01, a 52-week low, 4 down days in a row
Oct 13, 2026 β€” EOCN dips 1.7% to $3.16, a 52-week low, 3 down days in a row
Oct 12, 2026 β€” EOCN slides 9.0% to $3.22, a 52-week low
Oct 9, 2026 β€” EOCN dips 2.2% to $3.54
Oct 8, 2026 β€” EOCN jumps 4.7% to $3.62
Oct 7, 2026 β€” EOCN rises 2.9% to $3.46
Oct 6, 2026 β€” EOCN dips 2.6% to $3.36, a 52-week low
Oct 5, 2026 β€” EOCN slides 4.4% to $3.45
Oct 2, 2026 β€” EOCN jumps 6.0% to $3.61

EOCN latest news & SEC filings

Every SEC filing by or about EOCN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Sep 9, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-041872

Sep 8, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-041656

Sep 3, 2026 Β· Form EFFECT β€” EFFECT filing

EFFECT filing

Source: SEC EDGAR filing 9999999995-26-002874

Sep 3, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-041357

Sep 2, 2026 Β· Form POS AM β€” POS AM filing

POS AM filing

Source: SEC EDGAR filing 0001493152-26-041245

Sep 2, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-041239

Sep 2, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-041231

Aug 19, 2026 Β· Form 6-K/A β€” 6-K/A filing

6-K/A filing

Source: SEC EDGAR filing 0001493152-26-039207

Aug 19, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-039109

Aug 17, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-038663

Aug 14, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-038436

Jul 31, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-035621

Jul 29, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-035185

Jul 28, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-034933

Jul 22, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-034237

Things to know before you trade EOCN

EOCN market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 20262.913.092.332.8510.97K
Oct 15, 20262.923.162.923.052.00K
Oct 14, 20263.133.132.673.019.80K
Oct 13, 20263.233.373.103.169.10K
Oct 12, 20263.413.413.223.229.50K
Oct 9, 20263.463.603.463.544.70K
Oct 8, 20263.613.633.423.6214.80K
Oct 7, 20263.493.633.353.468.50K
Oct 6, 20263.453.563.283.3610.20K
Oct 5, 20263.553.623.453.457.70K
Oct 2, 20263.333.623.263.614.90K
Oct 1, 20263.143.623.123.4012.60K
Sep 30, 20263.453.493.393.492.60K
Sep 29, 20263.603.633.503.555.60K
Sep 28, 20263.463.633.463.633.90K
Sep 25, 20263.623.803.563.633.40K
Sep 24, 20263.753.753.623.623.00K
Sep 23, 20263.473.653.463.625.40K
Sep 22, 20263.673.803.453.6215.80K
Sep 21, 20263.333.663.333.503.10K

About Galmed Pharmaceuticals

Galmed Pharmaceuticals (EOCN) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in RAMAT GAN, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1595353.

EOCN board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Allen BaharaffChief Executive OfficerMar 18, 2026
Carol L BrosgartDirectorMar 18, 2026
Shmuel NirDirectorMar 18, 2026
Amir PoshinskiDirectorMar 18, 2026
David SidranskyDirectorMar 18, 2026

Executive officers

NameTitleLatest filing
Allen BaharaffChief Executive OfficerMar 18, 2026
Doron Leib CohenChief Financial OfficerMar 18, 2026
Guy NehemyaChief Operating OfficerMar 18, 2026
Brueck Liat NissimovChief Scientific OfficerMar 18, 2026
Yohai StenzlerChief Accounting OfficerMar 18, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

EOCN financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
No annual XBRL figures available (foreign filers often report on Form 20-F).

Latest balance sheet: total assets $β€”, total liabilities $β€”, cash $β€”.

EOCN earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on EOCN

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.